Age-related changes in factor VII proteolysis in vivo

British Journal of Haematology

Volumn 94, Issue 2, 1996, Pages 407-412

  Ofosu, F A ^a   Craven, S ^a   Dewar, L ^a   Anvari, N ^a   Andrew, M ^a   Blajchman, M A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

factor VIIa; prothrombin fragment 1+2; thrombin antithrombin III; tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; ANTITHROMBIN III; ENZYME PRECURSOR; PROTHROMBIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

AGE; ARTICLE; CHILD; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOSIS; ADOLESCENT; ADULT; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7A BLOOD LEVEL; CONTROLLED STUDY; ENZYME SYNTHESIS; HEMATOLOGICAL PARAMETERS; MIDDLE AGED; POSTOPERATIVE THROMBOSIS; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PROTHROMBIN BLOOD LEVEL; SCHOOL CHILD; YOUNG ADULT;

EID: 0029920205     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1793.x     Document Type: Article

References (28)

1. Bachman, F. & Leyvrac, P.F. (1994) Low-molecular weight heparins for prevention of venous thromboembolism following orthopedic surgery. Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thrombolic Diseases (ed. by H. Bounameaux), pp. 187-212. Marcel Dekker, New York.
2. Bauer, K.A., Weiss, L.M., Sparrow, S.D., Vokomas, P.S. & Rosenberg, R.D. (1987) Aging associated changes in indices of thrombin generation and protein C activation in humans. Journal of Clinical Investigation, 80, 1527-1534.
3. Comp, P.C. & Esmon, C.T. (1984) Recurrent venous thromboembolism in patients with a partial deficiency of protein S. New England Journal of Medicine, 311, 1525.
4. Dahlback, B. (1995) Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. Journal of Internal Medicine, 237, 221-227.
5. Demers, C., Ginsberg, J.S., Hirsh, J., Henderson, P. & Blajchman, M.A. (1992) Thrombosis in antithrombin-III-deficient persons: report of a large kindred and literature review. Annals of Internal Medicine, 116, 754-761.
6. Ginsberg, J.S., Brill-Edwards, P., Panju, A., Patel, A., McGinnis, J., Smith, F., Dale, I., Johnstone, M. & Ofosu, F.A. (1995) Preoperative plasma levels of thrombin-antithrombin III complexes correlate with the development of venous thrombosis after major hip or knee surgery. Thrombosis and Haemostasis, 74, 602-605.
7. Girolami, A., Simioni, P., Lazzaro, A.R. & Cordiano, I. (1989) Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. Thrombosis and Haemostasis, 61, 144-147.
8. Gouin-Thibault, I., Dewar, L., Kulczycky, M., Sternbach, M. & Ofosu, F.A. (1995) Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo. British Journal of Haematology, 90, 669-680.
9. Griffin, J.H., Evatt, B., Zimmerman, T.S., Kleis, A.J. & Wideman, C. (1981) Deficiency of protein C in congenital thrombolytic disease. Journal of Clinical Investigation, 68, 1370-1377.
10. Hoffman, C.J., Miller, R.H., Lawson, W.E. & Hultin, M.B. (1989) Elevation of factor VII activity and young adults at risk of ischemic heart disease. Journal of the American College of Cardiology, 14, 941-946.
11. Howard, P.R., Bovill, E.G., Pike, J., Church, W.R. & Tracy, R.P. (1994) Factor VII antigen levels in a healthy blood donor population. Thrombosis and Haemostasis, 72, 21-27.
12. Kannel, W.B., Wolf, P.A., Castelli, W.P. & D'Angelo, R.B. (1987) Fibrinogen and risk of cardiovascular disease: the Framingham Study. Journal of the American Medical Association, 258, 1183-1186.
13. Meade, T.W. (1981) Risk associated in thrombotic disorders. Clinical Haematology, 10, 391-405.
14. Meade, T.W., Mellows, S., Brozovic, M., Miller, G.J., Chakrabarti, R.R., North, W.R.S., Haines, A.P., Stirling, Y., Imeson, J.D. & Thompson, S.G. (1986) Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet, ii, 533-537.
15. Merlini, P.A., Ardissino, D., Oltrana, L., Broccolino. M., Coppala, R. & Mannucci, P.M. (1995) Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arteriosclerosis, Thrombosis and Vascular Biology, 15, 1675-1679.
16. Modi, G.J., Blajchman, M.A. & Ofosu, F.A. (1984) The isolation of prothrombin, factor IX and factor X from factor IX concentrates. Thrombosis Research, 36, 557-547.
17. Morrissey, J.H., Macila, B.G., Neuenschwander, P.F. & Comp, P.C. (1993) Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood, 81, 734-744.
18. Ofosu, F.A., Choay, J., Anvari, N., Smith, L.M. & Blajchman, M.A. (1990) Inhibitor of factor V activation by dermatan sulfate and the synthetic pentasaccharide with high affinity to antithrombin III. European Journal of Biochemistry, 193, 485-493.
19. Ofosu, F.A., Hirsch, J., Esmon, C.T., Modi, G.J., Smith, L.M., Anvari, N., Buchanan, M.R., Fenton, J.W., II & Blajchman, M.A. (1989) Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochemical Journal, 257, 143-150.
20. Ofosu, F.A., Leclerc, J., Delorme, F., Craven, S., Shafai, S., Frewin, L. & Blajchman, M.A. (1992a) The low molecular weight heparin enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. British Journal of Haematology, 82, 391-399.
21. Ofosu, F.A., Levine, M., Craven, S., Dewar, L., Shafai, S. & Blajchman, M.A. (1992b) Prophylactically equivalent doses of enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent. British Journal of Haematology, 82, 400-405.
22. Pelzer, H., Schwarz, A. & Heimburger, M. (1988) Determination of thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thrombosis and Haemostasis, 59, 101-106.
23. Pelzer, H., Schwartz, A. & Stuber, W. (1991) Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thrombosis and Haemostasis, 65, 153-159.
24. Smith, E. & Ashall, C. (1985) Fibrinolysis and plasminogen concentration in aortic intima and relation to death following myocardial infarction. Atherosclerosis, 55, 171-186.
25. Suzuki, T., Yamauchi, K., Matsushita, T., Furumichi, T., Furui, H., Tsuzuki, J. & Saito, H. (1991) Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clinical Cardiology, 14, 731-756.
26. Thompson, S.G., Kienast, J. & Pyke, S.D.M. (1995) Hemostatic factors and the risk for myocardial infarction or sudden death in patients with angina pectoris. New England Journal of Medicine, 332, 635-641.
27. Wilhelmson, L., Svardsudd, K., Korsan-Bengtsen, K., Larsson, B., Welin, L. & Tibblin, C. (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. New England Journal of Medicine, 311, 501-505.
28. Yarnell, J.W.G., Baker, I., Sweetman, P.M., Bainton, D., O'Brien, J.R., Whitehead, P.J. & Elwood, P.C. (1991) Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation, 83, 836-844.